Kiora Pharmaceuticals, Inc. · NASDAQ:KPRX
Kiora Pharmaceuticals — IPO Roadshow (July 2022)
34 slides from Kiora Pharmaceuticals's IPO roadshow presentation, Jul 14, 2022
Slide 1: Kiora Pharmaceuticals, Inc. Free Writing Prospectus
Kiora Pharmaceuticals, Inc. NASDAQ: KPRX Q3 2022 Filed pursuant to Rule 433 under the Securities Act of 1933, as amended Dated 7/14/2022 Registration Statement No. 333 - 264641
Slide 2: Forward Looking Statements
2 Forward Looking Statements Some of the statements in this presentation are “forward - looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 . These “forward - looking” statements include statements relating to, among other things, the d
Slide 3: Risk Factors
Risk Factors peop eepertine rie oe erp eeepc penta ey Financial Condition and Results of Operations,” any of which may be relevant to decisions regarding an investment in or ownership of our securities. The occurrence of any lela ieee es objectives. We have organized the description of these risks i
Slide 4: Free Writing Prospectus
4 Free Writing Prospectus This presentation highlights basic information about the Company and the offering . Because it is a summary that has been prepared solely for informational purposes, it does not contain all of the information that you should consider before investing in our Company . Except
Slide 5: Corporate Overview
5 Development stage company focused on rare & underserved ophthalmic diseases New executive leadership KIO - 301: Small molecule to restore vision in Retinitis Pigmentosa (RP) KIO - 101: Small molecule to treat Ocular Presentation of Rheumatoid Arthritis (OPRA) bm] Opportunity for value through mult
Slide 6: Development Pipeline
6 Indication Product Formulation Development Stage Anticipated Near - Term Milestones Pre - clinical Phase 1 Phase 2 Phase 3 Posterior Segment Retinitis Pigmentosa (Mutation Agnostic) KIO - 301 IVT Expect to initiate Phase 1b in Q3 2022 Anterior Segment Ocular Presentation of Rheumatoid Arthritis KI
Slide 7: Upcoming Planned Milestones
7 Upcoming Planned Milestones CTA – Clinical Trial Application (Australia), PCED – Persistent Corneal Epithelial Defect, ODD – Orphan Drug Designation, OPRA – Ocular Presentation of Rheumatoid Arthritis Q2 2022 Q3 2022 Q4 2022 Q1 2023 KIO - 301 Phase 1b CTA Submitted KIO - 301 Full Data in Retinitis
Slide 8: KIO-301 Retinitis Pigmentosa Photoswitch
8 KIO - 301 Target Population: Retinitis Pigmentosa Product: Small Molecule Photoswitch for Retinal Reanimation IP: Anticipated through 2041* * Also granted 7 years orphan drug regulatory exclusivity
Slide 9: Retinitis Pigmentosa: High Unmet Need with No Approved Therapeutics
9 Prevalence ▪ 1 : 3,500 worldwide ▪ Approximately 100,000 in US Etiology ▪ 50+ genetically distinct subtypes from 150+ mutations ▪ Inherited disease Clinical Presentation ▪ Night blindness, reduced visual field range and eventual loss of central vision ▪ Visual acuity declines Diagnosis ▪ Retinal e
Slide 10: KIO-301: Photoreceptors Degenerate While Downstream Neurons Remain Viable
10 KIO - 301: Photoreceptors Degeneration Whilst Downstream Neurons Remain Viable ▪ Normal human retina has about 120 million rods (black & white, night vision, movement) and 6 million cones (color) ▪ Photoreceptors die (rods first, then cones), unable to activate Bipolar cells and Retinal Ganglion
Slide 11: KIO-301: Turns RGCs ON in the Presence of Light
11 trans cis • In RP, photoreceptors are no longer viable => companion “signal” cells (RGCs) are not capable of being activated • KIO - 301 preferentially enters these RGCs and turns them “ON” in the presence of light* ‡ P2X7 is solely expressed on RGCs and amacrine cells in the retina. * Visual lig
Slide 12: KIO-301: Selectivity in Diseased Retinas
12 KIO - 301: Selectivity in Diseased Retinas Sci. Rep. 7, 45487 (2017) KIO - 301 is selective for RGCs in Degenerating Retinas Normal Retina Diseased Retina Light Dark Light Dark
Slide 13: KIO-301: Restore Vision in Daily-Life Regular Settings
13 Moonlight ƐƏƏ ‰ Cloudy Day Sunlight Light Intensity (photons/cm 2 · sec) KIO - 301: Restore Vision in Daily - Life Regular Settings Molecule Sensitive to a Broad Spectrum of Intensity and Wavelength Sci. Rep. 7, 45487 (2017), Banghart, Trauner et al (2008) Wavelength (nm) Light Response Index
Slide 14: KIO-301: Phase 1b Study Design (ABACUS)
ƐƓ KIO - 301: Phase 1b Study Design (ABACUS) Open Label, Single Ascending Dose Trial – Single Site (Australia) ▪ Two cohorts, non - randomized, open - label, single IVT injection per eye ▪ Cohort 1 – NLP/LP patients; Cohort 2 – HM/CF patients ▪ Up to 6 patients ƒ Safety review conducted by Investiga
Slide 15: KIO-301 Next Steps
ƐƔ KIO - 301 Next Steps Initiate Phase 1b Clinical Trial
Slide 16: Significant Activity from Large Pharma
16 Significant Activity from Large Pharma ;u Allergan Novartis Astellas Santen Treatment: Gene Therapy Gene Therapy Cell Therapy Cell Therapy Small Molecule Valuation: $60M + up to $495M in earnouts $150M + up to $130M in earnouts $379M $62M + up to $190M in earnouts* $5.3M Clinical Phase at Time of
Slide 17: KIO-101 Ocular Presentation of Rheumatoid Arthritis
17 KIO - 101 Target Population: Ocular Presentation of Rheumatoid Arthritis (OPRA) Product: Ocular DHODH Inhibitor IP: Anticipated through 2039
Slide 18: Ocular Presentation of Rheumatoid Arthritis
18 Ocular Presentation of Rheumatoid Arthritis Ocular Surface Discomfort is the Most Common Complaint Among Patients Large unmet need ▪ OPRA affects approximately 500,000 people in the US ▪ Other autoimmune diseases have ocular manifestations potentially addressable by KIO - 101 Patient Journey Rheu
Slide 19: KIO-101 Specificity and Best-in-Class Potency
19 *As of April 2021, RA – Rheumatoid Arthritis, MS – Multiple Sclerosis, AML – Acute Myeloid Leukemia, UC – Ulcerative Colitis, CD – Crohn’s Disease KIO - 101 has demonstrated greater specificity and best in class potency Company Drug Status * Indication Comments Sanofi Arava (leflunomide) Approved
Slide 20: KIO-101 Mechanism: T Helper Cell Inhibition
20 KIO - 101 acts upstream to inhibit the number of T helper cells (T H 17) and suppresses their pro - inflammatory cytokine release Nat. Rev. Rheumatol. 10, 552 – 560 (2014) OPRA Signs & Symptoms are Mediated by T H Cells
Slide 21: KIO-101: Exploratory Phase 1b Ocular Surface Inflammation Trial
21 KIO - 101: Exploratory Phase 1b Ocular Surface Inflammation Trial Enrolled Patients with Ocular Surface Inflammation* (N=21, 14/7) Randomization Days 1 - 12 BID Dosing Day 20 Final Follow - up Cohort 4: KIO - 101 (0.15%) Cohort 4: Placebo Enrolled healthy volunteer s (N=24, 8/cohort) Dose Escalat
Slide 22: KIO-101 Key Data Summary
22 KIO - 101 - 1101 Key Data Summary Slide* Safety & Tolerability ▪ Low & mid dose tolerated in healthy patients with ocular surface inflammation (OSI) ▪ High dose (0.3%) inconclusive & awaiting sub - chronic tox * Presented April 26, 2022 @ American Society of Cataract & Refractive Surgery (ASCRS)
Slide 23: KIO-101: Phase 2 Study Design
23 KIO - 101: Phase 2 Study Design Randomized, Multicenter, Double Masked, Multiple Ascending Dose Trial (Australia, EU, CA) ▪ Three - arm, randomized (1:1:1), controlled, double masked, 90 - day BID topical dosing ▪ Dx of RA (or other AI disease), conjunctival hyperemia, ODS - VAS ▪ Up to 120 patie
Slide 24: KIO-101 Next Steps
24 Ŋ ƐƏƐ Ĺ;Š|"|;rv mbঞ-|;_-v; Ƒ Ѵbmb1-Ѵ$ub-Ѵ ▪ Evaluate safety, tolerability, and efficacy in patients with ocular presentation of rheumatoid arthritis ▪ Expect to initiate Phase 2 clinical trial in the 2 nd half of 2022 ▪ Expect topline data by Q1 2024
Slide 25: KIO-201 Ocular Surface Wound Healing
25 KIO - 201 Target Population: Ocular Surface Wound Healing Product: Synthetic Modified Hyaluronic Acid IP: Through 2034* * Subject to 7 years regulatory exclusivity if ODD granted
Slide 26: KIO-201: Summary
26 KIO - 201: Summary Ŗ)-vu;]†Ѵ-|;7-v-l;7b1-Ѵ7;ˆb1;†mঞѴ ƑƏƑƏ l;ub1-m1-7;l‹o=r_|_-ѲloѲo]‹Ķ1†Ѳ-u"†u];u‹;‰vثrubѲ Ǝƍ Ķ ƏƍƎƔ ƒ Ŋ ƑƏƐ bv0-v;7om-lo7bC;7=oul o=|_;m-|†u-ѴroѴ‹l;u_‹-Ѵ†uomb1-1b7 Őő ƒ bv-l-|;ub-Ѵ‰b|_-_b]_ˆbv1ovb|‹ |_-|ruolo|;v‰o†m7_;-Ѵbm]0‹ ;m-0Ѵbm];m_-m1;71;ѴѴlb]u-ঞom ƒ Ɣ 1Ѵbmb1-Ѵ|ub-Ѵv1olrѴ;|
Slide 27: KIO-201: Phase 2 Study Design
27 Ŋ ƑƏƐ Ĺ_-v; Ƒ "|†7‹ ;vb]m "bm]Ѵ; Ŋ ulķr;m-0;Ѵ$ub-Ѵ ŋ "bm]Ѵ;"b|;Ő;Šb1oő -‹ ƑƐ (bvb| Ɠ KIO - 201 (0.75%) Day 1 Visit 1 Day 7 Visit 2 Day 14 Visit 3 ▪ Single - arm, open label, 28 days 6x daily topical dosing ▪ Dx of Stage 1 or 2 PCED ▪ Up to 10 patients ƒ "-=;|‹ ş |oѴ;u-0bѴb|‹ ƒ ѷo=r-ঞ;m|v_;-Ѵ;7Őƺ
Slide 28: KIO-201: Next Steps
28 KIO - 201: Next Steps mbঞ-|;_-v; Ƒ Ѵbmb1-Ѵ$ub-Ѵ ƒ ;uvbv|;m|oum;-Ѵrb|_;Ѵb-Ѵ ;=;1|v ƒ mbঞ-|;7_-v; Ƒ 1Ѵbmb1-Ѵ|ub-Ѵbm ƑƑƏƑƑ ƒ Šr;1||orѴbm;7-|-bm ƐƑƏƑƒ ƒ ur_-m u†] ;vb]m-ঞom;Šr;1|;7bm ƒƑƏƑƑ ƒ bv1†vvbomv‰b|_ ;Šr;1|;7bm|_; Ƒ m7 _-Ѵ=o= ƑƏƑƑ
Slide 29: Financials & Capitalization
29 Financials & Capitalization Capitalization as of April 22, 2022 Common Stock Equivalents Common Stock 12,663,965 Series D Convertible Preferred (convertible @ $3.5321 / share) 2,089 Warrants (WAEP $4.99) 6,757,180 Options (WAEP $7.85) 603,150 RSUs 60,152 Total Fully Diluted 20,086,536 As of Dec 3
Slide 30: Leadership Team
30 Leadership Team Brian M Strem, PhD President & CEO Susan Drexler, CPA Financial Consultant "|;=-m"r;uѴķ_ ( ŋ şr;u-ঞomv ub1 -mb;Ѵvķ ķ _b;= ;ˆ;Ѵorl;m|L1;u Angela Dentiste, MBA VP – Clinical Operations
Slide 31: Board of Directors
31 Board of Directors Brian M Strem, PhD President & CEO Paul Chaney Chairman Aron Shapiro ;m-‹uom u-ˆ;;m$‹Ѵ; David Hollander, MD, MBA Erin Parsons
Slide 32: Scientific Advisory Board
32 Scientific Advisory Board Daniel Durrie, MD Russel Van Gelder, MD, PhD _-uѴb;)‹ho@ķ (b1|ou;u;Œķ Francis Mah, MD Paul Karpecki, OD, FAAO Allen Ho, MD, PhD Christine Kay, MD, PhD Vitreo Retinal ASSOCIATES
Slide 33: Corporate Overview Summary
33 ourou-|;!;1-r ;ˆ;Ѵorl;m|v|-];1olr-m‹=o1†v;7omu-u;ş†m7;uv;uˆ;7or_|_-Ѵlb17bv;-v;v New executive leadership KIO - 301: Small molecule to restore vision in Retinitis Pigmentosa KIO - 101: Small molecule to treat Ocular Presentation of Rheumatoid Arthritis KIO - 201: Cross - linked hyaluronic acid for
Slide 34: Contact
om|-1|Ĺ bm=oŠhbou-r_-ul-ĺ1ol